Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

The Oxford-Harrington Rare Disease Centre initiates first disease priority area: Friedreich's Ataxia

The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

Friedreich’s Ataxia (FA) is a debilitating, life-shortening, degenerative neuromuscular rare disorder, with onset during childhood. Despite high levels of existing medical research around FA, significant further progress is needed to advance new treatments.

The Oxford-Harrington Rare Disease Centre (OHC) has the expertise and capability to contribute to the major effort underway aimed at developing effective treatments for FA in the near future. The OHC combines the University of Oxford and the Harrington Discovery Institute's world-leading strengths in research and therapeutics development. The OHC was formed to set the science and innovation agenda, driving cutting-edge rare disease breakthroughs to address the unmet need in rare disease across the globe and to deliver major clinical impact for patients. Friedreich’s Ataxia is a compelling initial focus area given this goal.

Read the Full article here

SHARE

FacebookTwitterLinkedInYoutube

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator